What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 3).

What question did this study set out to answer?

To evaluate the efficacy and safety of upadacitinib in patients with giant cell arteritis over two years.

View Full Paper

Ask AI

Bookmark

Authors

Phase 3 trial shows upadacitinib maintains remission and reduces glucocorticoid use in giant cell arteritis patients.

To evaluate the efficacy and safety of upadacitinib in patients with giant cell arteritis over two years.
Analyzed patients from the SELECT-GCA trial
Randomized controlled trial design with a 52-week initial period followed by a 52-week extension
Patients aged ≥50 with active GCA received UPA15 or placebo with glucocorticoid taper
42% achieved sustained remission for ≥24 weeks during the first period
67.3% of those on continuous UPA15 maintained remission vs 28.6% who switched to placebo
UPA15 showed a 90% reduction in the risk of disease flare compared to placebo

Schmidt et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark